Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

35.88

Mkt cap

236B

Volume

211K

High

36.01

P/E Ratio

19.05

52-wk high

42.43

Low

35.76

Div yield

0.04

52-wk low

29.20

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) has entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC: RHHBY) to develop molecular glue degraders for cancer and neurological diseases. Monte Rosa will receive an upfront payment of $50 million and could receive future milestone payments exceeding $2 billion. Monte Rosa will lead discovery and preclinical activities, while Roche will pursue further preclinical and clinical development. Monte Rosa retains full ownership of its pipeline programs. The company's shares are down 15.30%.

Portfolio Pulse from Vandana Singh

October 17, 2023 | 3:13 pm

Prothena Corporation (NASDAQ:PRTA) is reportedly preparing for a potential sale, attracting interest from large drugmakers. The company has collaborations with Bristol Myers Squibb Co (NYSE:BMY), Roche Holding AG (OTC:RHHBY), and Novo Nordisk A/S (NYSE:NVO). Recently, Bristol Myers Squibb exercised its option to obtain exclusive worldwide commercial rights for PRX005, an anti-tau antibody for potentially treating Alzheimer's disease, and will pay Prothena $55 million. Prothena's shares are up 20% at $52.90.

Portfolio Pulse from Vandana Singh

October 16, 2023 | 3:28 pm

Roche's Genentech has presented new clinical and real-world data for Ocrevus, a treatment for individuals with relapsing or primary progressive multiple sclerosis, at the 9th Joint ECTRIMS-ACTRIMS Meeting.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 7:20 am

Blood tests for diagnosing Alzheimer's disease are in development but not yet approved by regulators or insurance reimbursement. Eisai Co Ltd's and Biogen Inc's new Alzheimer's drug, Leqembi, currently relies on cognitive assessments or invasive cerebrospinal fluid tests. Laboratory Corporation Of America Holdings and Quest Diagnostics Incorporated have introduced blood tests measuring amyloid, tau, and neurodegeneration. Eli Lilly And Co is working with Quanterix on an experimental tau biomarker blood test and has partnered with Roche Holdings AG to develop a test measuring blood levels of a different tau protein and a gene associated with Alzheimer's risk.

Portfolio Pulse from Vandana Singh

October 11, 2023 | 6:27 pm

Roche's Genentech has announced results from the Phase IV CHIMES trial evaluating Ocrevus in Black and Hispanic / Latinx people with relapsing multiple sclerosis.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 7:10 am

Roche's Genentech announced late-breaking Phase III results showing that subcutaneous injection of Ocrevus was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks. The safety profile of Ocrevus subcutaneous injection was consistent with the well-established safety profile of Ocrevus IV infusion. The 10-minute subcutaneous injection has potential to improve the treatment experience and expand usage for people with multiple sclerosis (MS) in centers with IV capacity limitations.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 7:08 am

Roche's Genentech has announced the topline results from its global Phase III BALATON and COMINO studies, which evaluated extended Vabysmo® treatment intervals for macular edema. The results of these studies could potentially impact the future use and sales of Vabysmo®.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 6:46 am

Roche Group's Genentech has presented results from the primary analysis of the ongoing RAINBOWFISH study at the 28th World Muscle Society Congress. The study assesses the efficacy and safety of Evrysdi® in babies.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 5:59 am

Roche announced that it will present new clinical and real-world data at the ECTRIMS-ACTRIMS 2023 show, demonstrating the strength of long-term outcomes in Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder (NMOSD).

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 7:17 am

Ionis Pharmaceuticals Inc has entered an agreement with Roche Holdings AG for two early-stage programs for RNA-targeting investigational medicines for Alzheimer's and Huntington's diseases. Roche gains exclusive worldwide rights and will be responsible for clinical development, manufacturing, and commercialization. Ionis will receive a $60 million upfront payment from Roche and is eligible to receive development, regulatory, and commercial milestone payments and tiered royalties. Analysts see Ionis as the premier enterprise developing Antisense Oligonucleotides therapies but foresee near-term commercial headwinds.

Portfolio Pulse from Vandana Singh

September 27, 2023 | 5:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.